In terms of alteration types, ITGA10 had high amplification rates in hepatocellular carcinoma (LIHC, 9.7%), BRCA (9.2%), and bladder urothelial carcinoma (BLCA, 9.0%), whereas it predominantly mutated in SKCM (7.8%). Here, ITGA10 is linked to bladder transitional cell carcinoma.